

**Supplementary Table 7.** Summary of drug repositioning for PSC and supporting evidence

Drug	P-value	Hepatotoxicity	Experimental evidence for PSC	Experimental evidence for other liver diseases	Clinical evidence for PSC	Clinical evidence for other liver diseases
Glatiramer acetate	0.006444	None				
Toilizumab	0.006531	Exist				
Fluoxetine	0.008047	None		25102273		
Mycophenolate	0.008346	None		17944887	15521841	
Glibenclamide	0.009906	None				
Mycophenolic acid	0.011734	None				
Dexamethasone	0.014653	None	30252871	34801933	14531538	16981272
Abiraterone	0.015011	None				
Sorafenib	0.015689	Exist				
Iodine	0.016171	None				10189125
Antipruritic	0.018417	None				
Calcitriol	0.022363	None	25712522	28596677		32966467
Verteporfin	0.024002	None		33655469		
Vancomycin	0.027267	Exist				
Atorvastatin	0.028131	None	34208774		30448601	

The numbers shown in the table represent PubMed Identifier (PMID) numbers, which provide evidence for the foundational research and clinical studies supporting the therapeutic effects of the respective drugs.  
PSC, primary sclerosing cholangitis